These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 32447795)

  • 41. The Shelby Clinic Medication-Assisted Treatment for Opioid Addiction.
    Penn CL
    J Ark Med Soc; 2016 Aug; 113(2):30-32. PubMed ID: 30047628
    [No Abstract]   [Full Text] [Related]  

  • 42. Medication-assisted treatment for youth with opioid use disorder: Current dilemmas and remaining questions.
    Chang DC; Klimas J; Wood E; Fairbairn N
    Am J Drug Alcohol Abuse; 2018; 44(2):143-146. PubMed ID: 29190156
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Medication Treatment of Adolescent Opioid Use Disorder in Primary Care.
    Carney BL; Hadland SE; Bagley SM
    Pediatr Rev; 2018 Jan; 39(1):43-45. PubMed ID: 29292291
    [No Abstract]   [Full Text] [Related]  

  • 44. Diagnosis and Management of Opioid Use Disorder in Hospitalized Patients.
    Herscher M; Fine M; Navalurkar R; Hirt L; Wang L
    Med Clin North Am; 2020 Jul; 104(4):695-708. PubMed ID: 32505261
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Datapoints: regional variation in benzodiazepine prescribing for patients on opioid agonist therapy.
    Park TW; Bohnert AS; Austin KL; Saitz R; Pizer SD
    Psychiatr Serv; 2014 Jan; 65(1):4. PubMed ID: 24382761
    [No Abstract]   [Full Text] [Related]  

  • 46. Flexible Buprenorphine/Naloxone Treatment Models: Safe and Effective in Reducing Opioid Use Among Persons With Prescription Opioid Use Disorder.
    Saunders EC
    Am J Psychiatry; 2022 Oct; 179(10):699-701. PubMed ID: 36181331
    [No Abstract]   [Full Text] [Related]  

  • 47. Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex - United States, March 2019 - December 2020.
    Cremer LJ; Board A; Guy GP; Schieber L; Asher A; Parker EM
    Drug Alcohol Depend; 2022 Mar; 232():109192. PubMed ID: 35065513
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report.
    Crowley D; Delargy I
    Harm Reduct J; 2020 Jul; 17(1):49. PubMed ID: 32680520
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Opioid treatment programs, telemedicine and COVID-19: A scoping review.
    Chan B; Bougatsos C; Priest KC; McCarty D; Grusing S; Chou R
    Subst Abus; 2022; 43(1):539-546. PubMed ID: 34520702
    [No Abstract]   [Full Text] [Related]  

  • 50. Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
    Sigmon SC; Bigelow GE
    Addiction; 2017 Mar; 112(3):386-387. PubMed ID: 27561982
    [No Abstract]   [Full Text] [Related]  

  • 51. Buprenorphine Opioid Treatment During the COVID-19 Pandemic.
    Luigi M; Luo M; Maes EJP
    JAMA Intern Med; 2021 Aug; 181(8):1135. PubMed ID: 33843962
    [No Abstract]   [Full Text] [Related]  

  • 52. Buprenorphine Opioid Treatment During the COVID-19 Pandemic-Reply.
    Nguyen TD; Saloner B; Stein BD
    JAMA Intern Med; 2021 Aug; 181(8):1135-1136. PubMed ID: 33843947
    [No Abstract]   [Full Text] [Related]  

  • 53. Deploying science to change hearts and minds: Responding to the opioid crisis.
    Walsh SL; Long KQX
    Prev Med; 2019 Nov; 128():105780. PubMed ID: 31319116
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treating Patients With Opioid Use Disorder in Their Homes: An Emerging Treatment Model.
    Uscher-Pines L; Huskamp HA; Mehrotra A
    JAMA; 2020 Jul; 324(1):39-40. PubMed ID: 32459292
    [No Abstract]   [Full Text] [Related]  

  • 55. A health crisis within a health crisis: Opioid access in the COVID-19 pandemic.
    Narayan A; Balkrishnan R
    Subst Abus; 2021; 42(2):148-152. PubMed ID: 33849399
    [TBL] [Abstract][Full Text] [Related]  

  • 56. College students' perceived knowledge of and perceived helpfulness of treatments for opioid use disorder at two American universities.
    Andraka-Christou B; Nguyen T; Harris S; Madeira J; Totaram R; Randall-Kosich O; Atkins D; Ford J
    Am J Drug Alcohol Abuse; 2020 Sep; 46(5):589-603. PubMed ID: 32543922
    [No Abstract]   [Full Text] [Related]  

  • 57. Opioid Use Disorder and Pregnancy.
    O'Donnell FT; Jackson DL
    Mo Med; 2017; 114(3):181-186. PubMed ID: 30228577
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Community Partnership to Improve Access to Buprenorphine in a Homeless Population.
    Leo P; Gastala N; Fleurimont J; Messmer S; Maes P; Richardson J; Neeb C; Stackhouse N; Koruba S; Watson DP
    Ann Fam Med; 2021; 19(1):85. PubMed ID: 33431401
    [No Abstract]   [Full Text] [Related]  

  • 59. Use and misuse of opioid agonists in opioid addiction.
    Modesto-Lowe V; Swiezbin K; Chaplin M; Hoefer G
    Cleve Clin J Med; 2017 May; 84(5):377-384. PubMed ID: 28530896
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.